Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 3Paresthesia 2Neurotoxicity Syndromes 2Neoplasm Metastasis 2

Interventions

Paclitaxel 8Oxaliplatin 6Carboplatin 5Vincristine 4Radiotherapy 4Mental Status and Dementia Tests 4Leucovorin 4Amifostine 4Taxes 3Sodium Chloride 3Procarbazine 3Methotrexate 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Cytarabine 3Cyclophosphamide 3Cisplatin 3xaliproden 2glucarpidase 2Surveys and Questionnaires 2Rituximab 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Psychiatric Rehabilitation 2Prednisolone 2Magnesium Sulfate 2Folfox protocol 2Duloxetine Hydrochloride 2Doxorubicin 2Dexamethasone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neurotoxicity Syndromes × xaliproden × Clear all
NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Sanofi

Phase 3 Completed
879 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

NCT00272051 2006-09-13

XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy

Sanofi

Phase 3 Completed
620 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡